To date, there are no robust head-to-head comparisons of tyrosine kinase inhibitors (TKIs) regarding treatment flow in chronic myeloid leukaemia (CML). The available evidence is limited to observational studies of small size. This study aims to understand treatment patterns of TKIs and relevant side effects in CML